Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics:
- Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00)
- Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03)
- Clinical data with zongertinib for HER2-mutant NSCLC (6:35)
- Emerging data with sevabertinib for HER2-mutant NSCLC (14:41)
- Other investigational strategies being evaluated for HER2-mutant NSCLC (19:10)
- Summary of the current and future treatment landscape of HER2-mutant NSCLC (21:52)